Skip to main content
Premium Trial:

Request an Annual Quote

Singular Genomics Systems Raises $258M in Upsized IPO

NEW YORK – Singular Genomics Systems went public on the Nasdaq on Thursday after the firm priced its initial public offering of approximately 11.7 million shares at $22 per share the previous day, for anticipated gross proceeds of about $258.1 million before underwriting discounts, commissions, and other expenses.

In a Wednesday filing with the US Securities and Exchange Commission, the San Diego-based sequencing technology firm added nearly 2 million more shares to the offering. Previously, it had targeted a $187 million IPO.

Shares began trading on Thursday on the Nasdaq and rose to $29.00 per share before closing up 17 percent at $25.72.

JP Morgan, Goldman Sachs, Bank of America, and Cowen acted as joint bookrunning managers for the offering and as representatives of the underwriters. UBS also acted as a bookrunning manager. The underwriters have a 30-day option to purchase up to 1.5 million shares.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more